drugset / Trial / NCT00963365

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

NCT00963365

Phase 1 Withdrawn AstraZeneca
RandomizedCrossoverSingle-blind

Summary

The purpose of this study is to determine the safety of AZD6765 when given in single and multiple oral doses and to compare an oral and intravenous (IV) formulation of AZD6765 to placebo.

Timeline

Start
2008-11
Primary completion
2009-02
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject lanicemine Small molecule Oral

Indications

No indication recorded.